Status: Recruiting
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
To evaluate the efficacy and safety of induction chemotherapy combined with tislelizumab as neoadjuvant therapy in patients with locally advanced squamous cell carcinoma of the external auditory canal; to explore the improvement in the preservation rate of important neurovascular structures (including the facial nerve, internal carotid artery canal, sigmoid sinus, and posterior cranial nerves, etc.).
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Eye & ENT Hospital of Fudan UniversityUpdated: Jan 27, 2026Locations: 1
Eligibility criteria
Age > 18 years old and ≤ 80 years old [+9]
Ear tumors whose pathological type is not squamous cell carcinoma [+9]